Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice.
Asian Pac J Cancer Prev
; 14(5): 3079-83, 2013.
Article
in En
| MEDLINE
| ID: mdl-23803083
ABSTRACT
OBJECTIVE:
To investigate the effects of endostar, a recombined humanized endostatin, plus cisplatin on the growth, lymphangiogenesis and lymphatic metastasis of the Lewis lung carcinoma (LLC) in mice.METHODS:
A tumor model were established in C57BL/6 mice by intravenious transplantation of LLC cells. Then the mice were randomized to receive administration with NS, endostar, cisplatin, or endostar plus cisplatin. After the mice were sacrificed, tumor multiplicity, tumor size and lymph node metastasis were assessed. Then the expression of vascular endothelial growth factor-c (VEGF-C) and podoplanin were determined by immunohistochemical staining.RESULTS:
Endostar plus cisplatin significantly suppressed tumor growth. lymphatic metastasis and prolonged survival time of the mice without obvious toxicity. The inhibition of lymphatic metastasis was associated with decreased microlymphatic vessel density (MLVD) and expression of VEGF-C.CONCLUSIONS:
Endostar combined with cisplatin was more effective to suppress tumor growth and lymphatic metastasis than either agent alone. Thus this may provide a rational alternative for lung carcinoma treatment.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cisplatin
/
Carcinoma, Lewis Lung
/
Lymphatic Vessels
/
Endostatins
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Asian Pac J Cancer Prev
Journal subject:
NEOPLASIAS
Year:
2013
Document type:
Article
Affiliation country:
China